Tacrolimus and pimecrolimus for atopic dermatitis: Where do they fit in?

Archives of Dermatology

Volumn 142, Issue 9, 2006, Pages 1203-1205

  Bigby, Michael ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HYDROCORTISONE ACETATE; HYDROCORTISONE BUTYRATE; PIMECROLIMUS; TACROLIMUS;

ATOPIC DERMATITIS; BURNING SENSATION; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG TOLERABILITY; EMBASE; HUMAN; MEDLINE; NOTE; PRIORITY JOURNAL; SKIN INFECTION; SYSTEMATIC REVIEW;

ADMINISTRATION, CUTANEOUS; DERMATITIS, ATOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS; TACROLIMUS;

EID: 33748790920     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.9.1203     Document Type: Note

References (4)

1. Bigby M, Williams H. Appraising systematic reviews and meta-analyses. Arch Dermatol. 2003;139:795-798.
2. Wahn U, Bos JD, Goodfield M, et al; Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002; 110:e2 http://www.pediatrics.org/cgi/content/full/110/1/e2. Accessed July 7, 2006.
3. Minutes of the Pediatrics Advisory Committee sixth meeting, February 15, 2005. US Food and Drug Administration Web site. http://www.fda.gov/ohrms/ dockets/ac/05/transcripts/2005-4089T2.pdf. Accessed July 2, 2006.
4. Summary minutes of the Pediatric Advisory Committee, February 14-15, 2005. US Food and Drug Administration, Office of the Commissioner, Office of Pediatric Therapeutics and Office of Science and Health Coordination Web site. http: //www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4089m1_Minutes.pdf. Accessed July 2, 2006.